{"id":"https://openalex.org/W1978978593","doi":"https://doi.org/10.1158/1078-0432.ccr-14-0460","title":"Preclinical Optimization of MDM2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based Approach","display_name":"Preclinical Optimization of MDM2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based Approach","publication_year":2014,"publication_date":"2014-05-09","ids":{"openalex":"https://openalex.org/W1978978593","doi":"https://doi.org/10.1158/1078-0432.ccr-14-0460","mag":"1978978593","pmid":"https://pubmed.ncbi.nlm.nih.gov/24812409"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.ccr-14-0460","doi":"https://doi.org/10.1158/1078-0432.ccr-14-0460","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.ccr-14-0460","pdf_url":"https://aacrjournals.org/clincancerres/article-pdf/20/14/3742/2019636/3742.pdf","source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://aacrjournals.org/clincancerres/article-pdf/20/14/3742/2019636/3742.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5045446377","display_name":"Brian Higgins","orcid":"https://orcid.org/0000-0001-8272-5977","observed_orcids":["https://orcid.org/0000-0001-8272-5977"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Brian Higgins","raw_affiliation_strings":["Authors' Affiliations:\u20081Discovery Oncology;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Discovery Oncology;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067154728","display_name":"Kelli Glenn","orcid":"https://orcid.org/0000-0003-2874-5218","observed_orcids":["https://orcid.org/0000-0003-2874-5218"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kelli Glenn","raw_affiliation_strings":["2Drug Metabolism and Pharmacokinetics; and","Drug Metabolism and Pharmacokinetics; and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Drug Metabolism and Pharmacokinetics; and","institution_ids":[]},{"raw_affiliation_string":"Drug Metabolism and Pharmacokinetics; and","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078439299","display_name":"Antje\u2010Christine Walz","orcid":"https://orcid.org/0000-0002-2177-545X","observed_orcids":["https://orcid.org/0000-0002-2177-545X"]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"Roche (Switzerland)","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Antje Walz","raw_affiliation_strings":["4Modeling and Simulation, Pharma Research and Early Development, Hoffmann-La Roche, Inc., Basel, Switzerland","Modeling and Simulation, Pharma Research and Early Development, Hoffmann-La Roche, Inc., Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Modeling and Simulation, Pharma Research and Early Development, Hoffmann-La Roche, Inc., Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]},{"raw_affiliation_string":"Modeling and Simulation, Pharma Research and Early Development, Hoffmann-La Roche, Inc., Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112675021","display_name":"Christian Tovar","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Christian Tovar","raw_affiliation_strings":["Authors' Affiliations:\u20081Discovery Oncology;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Discovery Oncology;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019176023","display_name":"Zoran Filipovic","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Zoran Filipovic","raw_affiliation_strings":["Authors' Affiliations:\u20081Discovery Oncology;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Discovery Oncology;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066696385","display_name":"Sazzad Hussain","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sazzad Hussain","raw_affiliation_strings":["2Drug Metabolism and Pharmacokinetics; and","Drug Metabolism and Pharmacokinetics; and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Drug Metabolism and Pharmacokinetics; and","institution_ids":[]},{"raw_affiliation_string":"Drug Metabolism and Pharmacokinetics; and","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029407027","display_name":"Edmund Lee","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Edmund Lee","raw_affiliation_strings":["Authors' Affiliations:\u20081Discovery Oncology;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Discovery Oncology;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072303662","display_name":"Kenneth Daniel Kolinsky","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kenneth Kolinsky","raw_affiliation_strings":["Authors' Affiliations:\u20081Discovery Oncology;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Discovery Oncology;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078119352","display_name":"Shahid A. Tannu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Shahid Tannu","raw_affiliation_strings":["Authors' Affiliations:\u20081Discovery Oncology;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Discovery Oncology;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077577304","display_name":"Violeta Adames","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Violeta Adames","raw_affiliation_strings":["3Non-Clinical Safety, Pharma Research and Early Development, Hoffmann-La Roche, Inc., Nutley, New Jersey; and","Non-Clinical Safety, Pharma Research and Early Development, Hoffmann-La Roche, Inc., Nutley, New Jersey; and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Non-Clinical Safety, Pharma Research and Early Development, Hoffmann-La Roche, Inc., Nutley, New Jersey; and","institution_ids":[]},{"raw_affiliation_string":"Non-Clinical Safety, Pharma Research and Early Development, Hoffmann-La Roche, Inc., Nutley, New Jersey; and","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109149716","display_name":"Rosario Garrido","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Rosario Garrido","raw_affiliation_strings":["3Non-Clinical Safety, Pharma Research and Early Development, Hoffmann-La Roche, Inc., Nutley, New Jersey; and","Non-Clinical Safety, Pharma Research and Early Development, Hoffmann-La Roche, Inc., Nutley, New Jersey; and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Non-Clinical Safety, Pharma Research and Early Development, Hoffmann-La Roche, Inc., Nutley, New Jersey; and","institution_ids":[]},{"raw_affiliation_string":"Non-Clinical Safety, Pharma Research and Early Development, Hoffmann-La Roche, Inc., Nutley, New Jersey; and","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050081197","display_name":"Michael Linn","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michael Linn","raw_affiliation_strings":["3Non-Clinical Safety, Pharma Research and Early Development, Hoffmann-La Roche, Inc., Nutley, New Jersey; and","Non-Clinical Safety, Pharma Research and Early Development, Hoffmann-La Roche, Inc., Nutley, New Jersey; and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Non-Clinical Safety, Pharma Research and Early Development, Hoffmann-La Roche, Inc., Nutley, New Jersey; and","institution_ids":[]},{"raw_affiliation_string":"Non-Clinical Safety, Pharma Research and Early Development, Hoffmann-La Roche, Inc., Nutley, New Jersey; and","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077835854","display_name":"Christophe Meille","orcid":"https://orcid.org/0000-0001-8573-1248","observed_orcids":["https://orcid.org/0000-0001-8573-1248"]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"Roche (Switzerland)","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Christophe Meille","raw_affiliation_strings":["4Modeling and Simulation, Pharma Research and Early Development, Hoffmann-La Roche, Inc., Basel, Switzerland","Modeling and Simulation, Pharma Research and Early Development, Hoffmann-La Roche, Inc., Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Modeling and Simulation, Pharma Research and Early Development, Hoffmann-La Roche, Inc., Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]},{"raw_affiliation_string":"Modeling and Simulation, Pharma Research and Early Development, Hoffmann-La Roche, Inc., Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012238055","display_name":"David C. Heimbrook","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David Heimbrook","raw_affiliation_strings":["Authors' Affiliations:\u20081Discovery Oncology;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Discovery Oncology;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046690523","display_name":"Lyubomir T. Vassilev","orcid":"https://orcid.org/0000-0002-5557-0671","observed_orcids":["https://orcid.org/0000-0002-5557-0671"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lyubomir Vassilev","raw_affiliation_strings":["Authors' Affiliations:\u20081Discovery Oncology;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Discovery Oncology;","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5005659795","display_name":"Kathryn E. Packman","orcid":"https://orcid.org/0000-0002-2686-6481","observed_orcids":["https://orcid.org/0000-0002-2686-6481"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kathryn Packman","raw_affiliation_strings":["Authors' Affiliations:\u20081Discovery Oncology;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Discovery Oncology;","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5045446377"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":3.7479,"has_fulltext":true,"cited_by_count":63,"citation_normalized_percentile":{"value":0.94561243,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":93,"max":100},"biblio":{"volume":"20","issue":"14","first_page":"3742","last_page":"3752"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10583","display_name":"Cancer-related Molecular Pathways","score":0.9926999807357788,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10583","display_name":"Cancer-related Molecular Pathways","score":0.9926999807357788,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11829","display_name":"Mathematical Biology Tumor Growth","score":0.0010000000474974513,"subfield":{"id":"https://openalex.org/subfields/2611","display_name":"Modeling and Simulation"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mdm2-inhibitors","display_name":"MDM2 inhibitors","score":0.8659999966621399},{"id":"https://openalex.org/keywords/rg7388","display_name":"RG7388","score":0.9929999709129333},{"id":"https://openalex.org/keywords/nutlin","display_name":"nutlin","score":0.9649999737739563},{"id":"https://openalex.org/keywords/dosing-schedule-optimization","display_name":"dosing schedule optimization","score":0.7730000019073486},{"id":"https://openalex.org/keywords/intermittent-dosing","display_name":"intermittent dosing","score":0.9940000176429749},{"id":"https://openalex.org/keywords/pharmacokinetic-pharmacodynamic-modeling","display_name":"pharmacokinetic-pharmacodynamic modeling","score":0.8880000114440918},{"id":"https://openalex.org/keywords/modeling-and-simulation","display_name":"modeling and simulation","score":0.7860000133514404},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.5009999871253967},{"id":"https://openalex.org/keywords/rg7112","display_name":"RG7112","score":0.753000020980835},{"id":"https://openalex.org/keywords/tolerability","display_name":"tolerability","score":0.75},{"id":"https://openalex.org/keywords/phase-i-clinical-trial-design","display_name":"phase I clinical trial design","score":0.6710000038146973}],"concepts":[{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.8607722520828247},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.7071170210838318},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7069019079208374},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.558134138584137},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5482252240180969},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.5125853419303894},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.14559194445610046}],"mesh":[{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D001859","descriptor_name":"Bone Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D001859","descriptor_name":"Bone Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D001859","descriptor_name":"Bone Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008819","descriptor_name":"Mice, Nude","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008819","descriptor_name":"Mice, Nude","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008819","descriptor_name":"Mice, Nude","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011759","descriptor_name":"Pyrrolidines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D011759","descriptor_name":"Pyrrolidines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D011759","descriptor_name":"Pyrrolidines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D012516","descriptor_name":"Osteosarcoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D012516","descriptor_name":"Osteosarcoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D012516","descriptor_name":"Osteosarcoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D017209","descriptor_name":"Apoptosis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017209","descriptor_name":"Apoptosis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017209","descriptor_name":"Apoptosis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D023041","descriptor_name":"Xenograft Model Antitumor Assays","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D023041","descriptor_name":"Xenograft Model Antitumor Assays","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D023041","descriptor_name":"Xenograft Model Antitumor Assays","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D048288","descriptor_name":"Imidazolines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D048288","descriptor_name":"Imidazolines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D048288","descriptor_name":"Imidazolines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D048288","descriptor_name":"Imidazolines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D048288","descriptor_name":"Imidazolines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D048288","descriptor_name":"Imidazolines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D051736","descriptor_name":"Proto-Oncogene Proteins c-mdm2","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D051736","descriptor_name":"Proto-Oncogene Proteins c-mdm2","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D051736","descriptor_name":"Proto-Oncogene Proteins c-mdm2","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D062366","descriptor_name":"para-Aminobenzoates","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D062366","descriptor_name":"para-Aminobenzoates","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D062366","descriptor_name":"para-Aminobenzoates","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1158/1078-0432.ccr-14-0460","doi":"https://doi.org/10.1158/1078-0432.ccr-14-0460","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.ccr-14-0460","pdf_url":"https://aacrjournals.org/clincancerres/article-pdf/20/14/3742/2019636/3742.pdf","source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"},{"id":"pmid:24812409","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/24812409","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical cancer research : an official journal of the American Association for Cancer Research","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.ccr-14-0460","doi":"https://doi.org/10.1158/1078-0432.ccr-14-0460","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.ccr-14-0460","pdf_url":"https://aacrjournals.org/clincancerres/article-pdf/20/14/3742/2019636/3742.pdf","source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"score":0.5,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W1978978593.pdf","grobid_xml":"https://content.openalex.org/works/W1978978593.grobid-xml"},"referenced_works_count":20,"referenced_works":["https://openalex.org/W1650797637","https://openalex.org/W1966757630","https://openalex.org/W1975404751","https://openalex.org/W1983635800","https://openalex.org/W1991167758","https://openalex.org/W1993263392","https://openalex.org/W2012184890","https://openalex.org/W2013406032","https://openalex.org/W2021991709","https://openalex.org/W2042316019","https://openalex.org/W2064330613","https://openalex.org/W2074642772","https://openalex.org/W2091818021","https://openalex.org/W2097933346","https://openalex.org/W2098748257","https://openalex.org/W2099907467","https://openalex.org/W2113370608","https://openalex.org/W2123017967","https://openalex.org/W2141735955","https://openalex.org/W2155906069"],"related_works":["https://openalex.org/W4311628015","https://openalex.org/W3191427281","https://openalex.org/W2087016115","https://openalex.org/W2254638634","https://openalex.org/W2369345461","https://openalex.org/W2141289501","https://openalex.org/W2960553615","https://openalex.org/W3043458966","https://openalex.org/W2162491061","https://openalex.org/W2307066354"],"abstract_inverted_index":{"PURPOSE:":[0],"Antitumor":[1],"clinical":[2,189,237,258],"activity":[3,206],"has":[4],"been":[5],"demonstrated":[6],"for":[7,15,70,245,256],"the":[8,16,35,42,59,82,88,91,118],"MDM2":[9],"antagonist":[10],"RG7112,":[11,234],"but":[12],"patient":[13],"tolerability":[14,227],"necessary":[17],"daily":[18,140,244],"dosing":[19,39,67,111,141,149,165,190],"was":[20,56,78,125,169],"poor.":[21],"Here,":[22],"utilizing":[23],"RG7388,":[24,214],"a":[25,147],"second-generation":[26],"nutlin":[27],"with":[28,131,210,230],"superior":[29],"selectivity":[30],"and":[31,109,145,180,219,243],"potency,":[32],"we":[33],"determine":[34,65],"feasibility":[36],"of":[37,44,61,84,90,153,166,178,213,233],"intermittent":[38,108,188,211],"to":[40,64,80,87,105,128,171],"guide":[41],"selection":[43],"initial":[45,137],"phase":[46],"I":[47],"scheduling":[48],"regimens.":[49],"EXPERIMENTAL":[50],"DESIGN:":[51],"A":[52],"pharmacokinetic-pharmacodynamic":[53],"(PKPD)":[54],"model":[55,77,98,120],"developed":[57],"on":[58,182],"basis":[60],"preclinical":[62,193],"data":[63,102,184],"alternative":[66,222],"schedule":[68],"requirements":[69],"optimal":[71],"RG7388-induced":[72,123],"antitumor":[73,92,205],"activity.":[74],"This":[75],"PKPD":[76],"used":[79,104],"investigate":[81],"pharmacokinetics":[83],"RG7388":[85,154,257],"linked":[86],"time-course":[89],"effect":[93],"in":[94,99,114,117,158],"an":[95],"osteosarcoma":[96],"xenograft":[97],"mice.":[100],"These":[101,221],"were":[103,155,254],"prospectively":[106],"predict":[107],"continuous":[110,132],"regimens,":[112],"resulting":[113],"tumor":[115,160],"stasis":[116],"same":[119],"system.":[121],"RESULTS:":[122],"apoptosis":[124],"delayed":[126],"relative":[127],"drug":[129],"exposure":[130],"treatment":[133],"not":[134],"required.":[135],"In":[136,162],"efficacy":[138],"testing,":[139],"at":[142,150],"30":[143],"mg/kg":[144,152,168,173],"twice":[146],"week":[148],"50":[151,167],"statistically":[156],"equivalent":[157,170],"our":[159],"model.":[161],"addition,":[163],"weekly":[164,241],"10":[172],"given":[174],"daily.":[175],"The":[176],"implementation":[177],"modeling":[179,218],"simulation":[181],"these":[183,196],"suggested":[185],"several":[186],"possible":[187],"schedules.":[191],"Further":[192],"analyses":[194],"confirmed":[195],"schedules":[197,212,253],"as":[198,215],"viable":[199],"options.":[200],"CONCLUSION:":[201],"Besides":[202],"chronic":[203,231],"administration,":[204],"can":[207],"be":[208],"achieved":[209],"predicted":[216],"through":[217],"simulation.":[220],"regimens":[223],"may":[224],"potentially":[225],"ameliorate":[226],"issues":[228],"seen":[229],"administration":[232],"while":[235],"providing":[236],"benefit.":[238],"Thus,":[239],"both":[240],"(qw)":[242],"five":[246],"days":[247],"(5":[248],"d":[249],"on/23":[250],"off,":[251],"qd)":[252],"selected":[255],"testing.":[259]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":5},{"year":2022,"cited_by_count":6},{"year":2021,"cited_by_count":7},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":6},{"year":2018,"cited_by_count":5},{"year":2017,"cited_by_count":5},{"year":2016,"cited_by_count":5},{"year":2015,"cited_by_count":14},{"year":2014,"cited_by_count":2}],"updated_date":"2026-10-04T09:36:47.201465","created_date":"2025-10-10T00:00:00"}